

Cancer 2015 - 2017 Measure Evaluation Recusals

The [NQF CDP Conflict of Interest Policy](#) requires that Committee members identified as having a potential conflict of interest in relation to specific measures must recuse themselves from evaluation and voting on those measures when seated on the Committee.

In the review of disclosure of interests submitted by Committee members, NQF is requiring the following recusals be made during the measure evaluation period.

Measures Under Review(February 22, 2016 – October 27, 2016)& Committee Member Recusals

Measure Number	Measure Title	Measure Steward	Committee Member Recusals
0219	Post breast conservation surgery irradiation	Commission on Cancer, American College of Surgeons	Matthew Facktor, MD, FACS Geisinger Medical Center
0220	Adjuvant hormonal therapy	Commission on Cancer, American College of Surgeons	Matthew Facktor, MD, FACS Geisinger Medical Center
0223	Adjuvant chemotherapy is considered or administered within 4 months (120 days) of diagnosis to patients under the age of 80 with AJCC III (lymph node positive) colon cancer	Commission on Cancer, American College of Surgeons	Matthew Facktor, MD, FACS Geisinger Medical Center
0225	At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer.	Commission on Cancer, American College of Surgeons	Matthew Facktor, MD, FACS Geisinger Medical Center
0381	Oncology: Treatment Summary Communication – Radiation Oncology	American Society for Radiation Oncology (ASTRO)	David J. Sher, MD, MPH UT Southwestern Medical Center Benjamin Movsas, M.D.



			Radiation Oncology, Henry Ford Health System
0382	Oncology: Radiation Dose Limits to Normal Tissues	American Society for Radiation Oncology (ASTRO)	David J. Sher, MD, MPH UT Southwestern Medical Center Benjamin Movsas, M.D. Radiation Oncology, Henry Ford Health System
0386	Oncology: Cancer Stage Documented	American Society of Clinical Oncology	Benjamin Movsas, M.D. Radiation Oncology, Henry Ford Health System
0389	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients	American Medical Association - Physician Consortium for Performance Improvement (AMA-PCPI)	Benjamin Movsas, M.D. Radiation Oncology, Henry Ford Health System
0390	Prostate Cancer: Adjuvant Hormonal Therapy for High Risk Prostate Cancer Patients	American Urological Association (AUA)	Gregary Bocsi, DO, FCAP University of Colorado Hospital Clinical Laboratory Benjamin Movsas, M.D. Radiation Oncology, Henry Ford Health System
0559	Combination chemotherapy is recommended or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0M0, or Stage IB - III hormone receptor negative breast cancer.	Commission on Cancer, American College of Surgeons	Matthew Facktor, MD, FACS Geisinger Medical Center
1822	External Beam Radiotherapy for Bone Metastases	American Society for Radiation Oncology	David J. Sher, MD, MPH UT Southwestern Medical Center Benjamin Movsas, M.D. Radiation Oncology, Henry Ford Health System
1853	Radical Prostatectomy Pathology Reporting	College of American Pathologists	Gregary Bocsi, DO, FCAP University of Colorado Hospital Clinical Laboratory
1854	Barrett's Esophagus	College of American Pathologists	Gregary Bocsi, DO, FCAP University of Colorado Hospital Clinical Laboratory
1855	Quantitative HER2 evaluation by IHC uses the	College of American	Gregary Bocsi, DO, FCAP



	system recommended by the ASCO/CAP guidelines	Pathologists	University of Colorado Hospital Clinical Laboratory
1857	HER2 negative or undocumented breast cancer patients spared treatment with HER2-targeted therapies	American Society of Clinical Oncology	Shelley Fuld Nasso, MPP National Coalition for Cancer Survivorship
1858	HER2 targeted therapies received by patients with AJCC stage I (T1c) – IV and HER2 positive breast cancer receiving adjuvant chemotherapy	American Society of Clinical Oncology	Shelley Fuld Nasso, MPP National Coalition for Cancer Survivorship
1878	HER2 testing for overexpression or gene amplification in patients with breast cancer	American Society of Clinical Oncology	Shelley Fuld Nasso, MPP National Coalition for Cancer Survivorship
2963	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients	Physician Consortium for Performance Improvement	Benjamin Movsas, M.D. Radiation Oncology, Henry Ford Health System